Beyond antibiotics—a paradigm shift toward bacteria-control-centric therapies

Antimicrobial resistance has emerged as a pressing global health concern, with the rise of multidrug-resistant (MDR) gram-negative bacteria posing a significant threat to public health. These bacteria have developed resistance to even the most powerful antibiotics, resulting in substantially higher mortality rates. In the face of this challenge, researchers are turning to polymyxins - a class of antibiotics that remain among the few treatment options available for severe infections caused by resistant Escherichia coli.

However, the widespread use of polymyxins is hampered by their serious side effects, which include kidney and nerve toxicity. These adverse reactions can have long-lasting and debilitating consequences for patients, limiting the potential benefits of these antibiotics. As a result, healthcare professionals are forced to carefully weigh the risks and benefits of using polymyxins, often reserving them for the most critical cases where alternative treatment options are unavailable. Despite these limitations, polymyxins remain a vital component of the arsenal against MDR gram-negative bacteria, and ongoing research aims to improve their safety and efficacy.

The search for more effective and safer antibiotics is an urgent priority, as the world grapples with the growing threat of antimicrobial resistance. Researchers are exploring new approaches, including the development of novel antibiotics and the discovery of alternative therapeutic strategies. By addressing the challenges posed by polymyxins and other last-line antibiotics, scientists hope to mitigate the risks associated with their use and ensure that these critical medications remain available for the most vulnerable patients.